SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering pioneering 3D bioprinting technology, announced today that it has been recognized as a 2015 Technology Pioneer by the World Economic Forum (WEF). Organovo is one of 24 companies honored for the ability to harness creativity to design and create transformative solutions.
"We are honored to be named a Technology Pioneer by the World Economic Forum for the innovation and power of Organovo's 3D bioprinting technology," said Keith Murphy, president and CEO of Organovo. "We see this as a recognition of our team's hard work and dedication to our mission to improve health and medicine on a global scale."
Organovo's leading, commercial 3D bioprinting technology enables the creation of functional human tissues that more accurately reproduce native tissues. The company develops a range of tissue and disease models for medical research, drug testing and therapeutic applications.
"The impact of technology continues to accelerate in all domains of society," said Fulvia Montresor, director, head of Technology Pioneers at the World Economic Forum. "To better understand the breadth and depth of this impact, CEOs and other leaders have come to depend on their interactions with the Technology Pioneers and their diverse and innovative solutions."
Each year since 2000, the World Economic Forum chooses its Technology Pioneers from hundreds of applicants that are vetted by a distinguished selection committee of technology and innovation experts.
Organovo and the 2015 Technology Pioneers will be honored at a ceremony on September 11 at the eighth Annual Meeting of the New Champions. The Meeting is the foremost gathering in Asia on science, technology, innovation and entrepreneurship.
More information about the World Economic Forum's Technology Pioneers programme can be found at http://www.weforum.org/techpioneers.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company plans to market the first product of a planned portfolio offering, 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing prior to the end of 2014, and remains on track to bring this breakthrough technology to customers. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 as well as our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
|SOURCE Organovo Holdings, Inc.|
Copyright©2014 PR Newswire.
All rights reserved